Theraly Fibrosis, Inc
디앤디파마텍
Baltimore, United States · Founded 2017 · $188.1M raised
- Headquarters
- Baltimore, Maryland
- Employees
- 1–10
- Founded
- 2017
- Business Model
- B2G
- Website
- ddpharmatech.com
- Total Funding
- $188.1M
- Last Round
- $137.1M Series BAug 2024
- Rounds
- 2
About
Theraly Fibrosis is a preclinical-stage biopharmaceutical company developing TLY012, a recombinant human TRAIL protein that selectively targets myofibroblasts to reverse established fibrosis. The company's pipeline targets systemic sclerosis, chronic pancreatitis, liver fibrosis, and NASH, with two FDA Orphan Drug Designations granted for TLY012. Theraly is a subsidiary of D&D Pharmatech, a global clinical-stage biotech.
Summary
Theraly Fibrosis, Inc is a Biotech company based in Baltimore, United States, founded in 2017. It has raised $188.1M in total across 2 rounds, most recently a $137.1M Series B round in Aug 2024. Investors include Octave Life Sciences, Smilegate Investment and Praxis.
Tech & App Stack
2 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Aug 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...